Picture supply: Getty Photos
Penny shares might be interesting investments because of their low share costs and potential for prime returns. Nevertheless, investing in these speculative small-cap shares carries larger danger than shopping for equities listed on the FTSE 100 or FTSE 250 indexes.
Volatility is a key concern. Buyers contemplating these high-risk funding propositions want the abdomen to endure huge share value actions in pursuit of portfolio good points. Briefly, they’re not for the faint-hearted.
One firm that’s no stranger to volatility is Creo Medical (LSE:CREO). This AIM-listed healthcare gadget enterprise specialises in minimally invasive surgical endoscopy. Buying and selling at a 52-week low after a chronic shedding streak, is immediately the right time to purchase this beaten-down penny inventory?
A falling share value
Creo Medical has seen its market cap evaporate lately as its share value has taken a battering. In the present day, the inventory market minnow’s valued for lower than £52m.
There are some worrying indicators on this penny inventory for potential traders to observe intently. The agency’s FY24 revenues failed to satisfy market expectations. The group complete of £30.4m represented a 1.3% decline in comparison with the prior yr’s determine of £30.8m. Frankly, it’s regarding to see the corporate going into reverse gear on such an important metric.
Creo Medical has additionally but to show a revenue. The board expects FY25 shall be one other loss-making yr. I’m fearful more money will must be raised earlier than the enterprise turns into a worthwhile enterprise, which will not be straightforward provided that it has traditionally skilled fundraising difficulties.
That mentioned, in February, the corporate secured £25m in web inflows from divesting a majority stake in its European consumables enterprise to a Chinese language medical gadget producer. Coupled with a £12.1m fairness increase final yr, Creo Medical has some monetary headroom for the close to future a minimum of.
Restoration potential
On the brilliant aspect, this month marked the business launch of a brand new product — the SpydrBlade Flex — within the UK and EU. This might present a much-needed increase for the corporate’s backside line. The multi-modal endoscopic gadget has promising purposes for minimally invasive therapy of colorectal most cancers.
As well as, the potential of Creo Medical’s core providing can’t be understated. Its flagship Speedboat product suite makes use of outstanding know-how. These tiny surgical devices provide surgeons a one-stop store to hold out incision, dissection, and coagulation procedures with no need to alter gadgets.
The market alternative is appreciable. Some analysts imagine the gastrointestinal endoscopic applied sciences market might be value between £2.32bn and £2.48bn. If Creo Medical can efficiently realise the business potential of its merchandise, the shares may in the end show to be a profitable funding at this early stage.
A penny inventory to think about?
Like all penny shares, Creo Medical faces vital dangers. The truth that the shares have been as soon as altering palms for practically £2.30, in comparison with 12.5p immediately, proves as a lot.
Nonetheless, the corporate’s danger/reward profile seems enticing to me proper now at this low valuation. Enchancment shall be wanted throughout a spread of core monetary yardsticks, however the agency’s distinctive patented applied sciences present vital promise.
So, is Creo Medical a cut price inventory? Fairly presumably! Discount of the yr? That’s most likely a stretch. However for traders with adequate danger appetites, I feel this penny share deserves consideration.
